» Articles » PMID: 16865538

Increased Hippocampal Nitric Oxide Synthase Activity and Stress Responsiveness After Imipramine Discontinuation: Role of 5HT 2A/C-receptors

Overview
Journal Metab Brain Dis
Publisher Springer
Specialties Endocrinology
Neurology
Date 2006 Jul 26
PMID 16865538
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic depressive illness may cause shrinkage of the hippocampus with stress-induced release of glutamate and nitric oxide possibly causally linked to this pathology. Poor antidepressant compliance may contribute to this pathology as well as to long term morbidity. However, antidepressant withdrawal-associated symptoms in depressed patients often reflect hyperserotonergia. The effect of chronic imipramine (IMI; 15 mg/kg/d ip x 3wks) treatment and withdrawal on swim stress responsiveness was studied in Sprague-Dawley rats together with assay of hippocampal NO synthase (NOS) activity. The dependence of any biobehavioral changes following IMI withdrawal on 5HT(2A/C) receptor-mediated events was studied using the 5HT(2A/C) receptor antagonist, ritanserin (RIT; 4 mg/kg/day ip x 7 days), administered alone or during IMI withdrawal. IMI significantly inhibited the situational stress response to forced swimming while also significantly decreasing NOS activity. IMI withdrawal was associated with a significant increase in swim immobility together with a significant increase in NOS activity compared to both control and IMI-treated groups. RIT re-established the anti-immobility effects and reversed NOS hyper-function during IMI withdrawal, although alone it increased NOS activity. Antidepressant discontinuation therefore increases stress responsiveness together with disinhibition of hippocampal NOS through a mechanism involving 5HT(2A/C) receptor activation. The resulting increased nitrergic activity may have significant implications for depressive illness and its treatment.

Citing Articles

A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study.

Majeed M, Nagabhushanam K, Mundkur L Medicine (Baltimore). 2023; 102(41):e35521.

PMID: 37832082 PMC: 10578737. DOI: 10.1097/MD.0000000000035521.


Ketamine alleviating depressive-like behaviors is associated with regulation of nNOS-CAPON-Dexras1 complex in chronic unpredictable mild stress rats.

Shen Y, Lv F, Min S, Hao X, Yu J Transl Neurosci. 2022; 13(1):309-319.

PMID: 36212606 PMC: 9508647. DOI: 10.1515/tnsci-2022-0245.


The effect of different antidepressant drugs on oxidative stress after lipopolysaccharide administration in mice.

Abdel-Salam O, Youssef Morsy S, Sleem A EXCLI J. 2017; 10:290-302.

PMID: 29033710 PMC: 5611632.


Methylene blue and its analogues as antidepressant compounds.

Delport A, Harvey B, Petzer A, Petzer J Metab Brain Dis. 2017; 32(5):1357-1382.

PMID: 28762173 DOI: 10.1007/s11011-017-0081-6.


Acute Stressors Reduce Neural Inhibition to Food Cues and Increase Eating Among Binge Eating Disorder Symptomatic Women.

Lyu Z, Jackson T Front Behav Neurosci. 2016; 10():188.

PMID: 27790097 PMC: 5061815. DOI: 10.3389/fnbeh.2016.00188.


References
1.
Coyle J, Price D, DeLong M . Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983; 219(4589):1184-90. DOI: 10.1126/science.6338589. View

2.
Floyd R . Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med. 1999; 222(3):236-45. DOI: 10.1046/j.1525-1373.1999.d01-140.x. View

3.
Orrenius S, McConkey D, Bellomo G, Nicotera P . Role of Ca2+ in toxic cell killing. Trends Pharmacol Sci. 1989; 10(7):281-5. DOI: 10.1016/0165-6147(89)90029-1. View

4.
Waypa G, Schumacker P . O(2) sensing in hypoxic pulmonary vasoconstriction: the mitochondrial door re-opens. Respir Physiol Neurobiol. 2002; 132(1):81-91. DOI: 10.1016/s1569-9048(02)00051-4. View

5.
Mohanakumar K, Muralikrishnan D, Thomas B . Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res. 2000; 864(2):281-90. DOI: 10.1016/s0006-8993(00)02189-2. View